Nykode Therapeutics AS (OTCMKTS:VACBF – Get Free Report) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 2,480 shares, a growth of 67.6% from the August 31st total of 1,480 shares. Based on an average trading volume of 600 shares, the days-to-cover ratio is presently 4.1 days.
Nykode Therapeutics AS Price Performance
Nykode Therapeutics AS stock opened at $0.45 on Thursday. The firm’s 50 day simple moving average is $0.37 and its 200 day simple moving average is $0.37. Nykode Therapeutics AS has a 1-year low of $0.32 and a 1-year high of $0.45.
Nykode Therapeutics AS Company Profile
Nykode Therapeutics AS is a Norwegian biotechnology company focused on developing targeted immunotherapies for cancer and autoimmune diseases. The company’s approach is designed to direct therapeutic payloads to specific immune cells, with the goal of generating targeted and durable immune responses.
Nykode’s technology platform, originally developed under the Vaccibody name, uses modular molecules that can target antigens to antigen-presenting cells and stimulate both cellular and antibody-based immunity.
Featured Stories
- Five stocks we like better than Nykode Therapeutics AS
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Nykode Therapeutics AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nykode Therapeutics AS and related companies with MarketBeat.com's FREE daily email newsletter.
